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Best Practices to Maximize the Use and Reuse of 
Quantitative and Systems Pharmacology Models: 
Recommendations From the United Kingdom Quantitative 
and Systems Pharmacology Network
Lourdes Cucurull-Sanchez1,*, Michael J. Chappell2, Vijayalakshmi Chelliah3, S. Y. Amy Cheung4,5, Gianne Derks6, Mark Penney7, 
Alex Phipps8, Rahuman S. Malik-Sheriff9, Jon Timmis10, Marcus J. Tindall11,12, Piet H. van der Graaf3,13, Paolo Vicini14,15 and 
James W. T. Yates16
The lack of standardization in the way that quantitative and systems pharmacology (QSP)  models are developed, tested, and 
documented hinders their reproducibility, reusability, and expansion or reduction to alternative contexts. This in turn under-
mines the potential impact of QSP in academic, industrial, and regulatory frameworks. This article presents a minimum set 
of recommendations from the UK Quantitative and Systems Pharmacology Network (UK QSP Network) to guide QSP practi-
tioners seeking to maximize their impact, and stakeholders considering the use of QSP models in their environment.
One of the key advantages of quantitative and systems 
pharmacology (QSP) modeling is its integrative and mod-
ular nature. This modular nature renders QSP an optimal 
scenario to reuse models by expanding them through the 
addition of more submodules, by reducing the number of 
submodels, or by translating existing modules to different 
contexts. 
QSP is gaining traction against the background of the 
exponential increase in the number of QSP publications in 
scientific journals since the release of two seminal papers1,2 
(see Figure 1), the emergence of the first scholarly jour-
nal dedicated to systems pharmacology,3 and the growing 
number of mathematical models of biology readily available 
through public databases (BioModels,4 CellML,5 DDMore6). 
However, QSP is only slowly climbing up the innovation 
 trigger slope of the Gartner Hype Cycle,7 which describes 
the maturity, adoption, and social application of emerging 
technologies through five consecutive phases (innova-
tion trigger, peak of inflated expectations, trough of disil-
lusionment, (positive) slope of enlightenment, and plateau 
of productivity). The consistent integration of QSP into the 
Model- Informed Drug Discovery and Development (MID3) 
strategy within the pharmaceutical industry still proves 
challenging. In addition, the growth rate of the number of 
QSP models in public databases is slow compared with 
the increase of QSP publications, as a result of the lack of 
resources, inadequate model documentation, and a decline 
in the direct submission of models to those repositories by 
their authors. Published models tend to be generated de 
novo rather than being the result of an expansion or modi-
fication of existing models. This situation is, to a significant 
extent, because of the lack of standardization in the way that 
QSP models are developed, tested, and documented when 
made available to the public community, which hinders 
their reproducibility, reusability, and expansion or reduc-
tion to alternative contexts. This gap has been somewhat 
quantified by Kirouac et al.,8 who found that only 4 out of 
12 model code files published in CPT: Pharmacometrics & 
Systems Pharmacology until October 2018 was executable. 
Transparency in reporting each stage of the modeling pro-
cess and the adoption of good practice in doing so would 
greatly increase the likelihood of a model being more widely 
adopted and used by others.9 This is particularly important 
if QSP is to become a standard accepted approach as part 
of regulatory submissions, as from a regulatory perspective, 
transparency and collaboration increase the validation and 
acceptance of a model. Regulatory reviewers of QSP mod-
els face the challenge of having only 1 to 3 months to repro-
duce the results, evaluate underlying assumptions, and test 
the model with other/new data.10
The ideal scenario is well illustrated by the filing in 2013 
of a recombinant human parathyroid hormone (rhPTH) for 
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the treatment of hypoparathyroidism.11 The US Food and 
Drug Administration (FDA) reviewers raised some concerns 
about the hypercalciuria being observed in the clinical study 
and used a publicly available calcium homeostasis QSP 
model12 to explore  alternative dosage regimens. This QSP 
model was built on two earlier published models: a model of 
systemic calcium homeostasis13 and a cellular model of the 
behavior of bone morphogenic units.14 The QSP simulations 
supported the hypothesis that increased dosing frequency 
or slow infusion could reduce hypercalciuria. This led the 
FDA to request from the sponsors a postmarketing clinical 
trial to evaluate the effects of dose and dosing regimens 
on the control of hypercalciuria, and to use a mechanistic 
model–based assessment of prior pharmacokinetic/phar-
macodynamic data to design this clinical trial.15 Had it not 
been for the publication and adequate development and de-
scription of those three models, the FDA would have missed 
the insight that led them to this impactful decision.
There are several common issues encountered by the 
modeling community when accessing models either from 
databases or peer- reviewed publications, which stem from 
this lack of documentation standards. They can be summa-
rized as follows:
1. The purpose and/or scope of the model is unclear 
and/or the underlying assumptions are either poorly 
or not stated. Often the structure of the model is 
provided without referring to the specific question 
or questions for which that model is intended. In 
other instances, the assumptions made to derive 
that structure or some of the parametric relationships 
are undeclared or vaguely described. The negative 
impact of poor descriptions of assumptions increases 
when the number of assumptions is high, which 
can be daunting to decision makers and collabo-
rators. These situations make it difficult for the reader 
to assess the contexts for which the model would 
be suitable for and/or to what extent it can be 
adapted to similar contexts.
2. The model and/or the publication lacks quantitative 
 information. Some models published in the mathemat-
ical biology space consist of little more than schema 
or networks describing the interactions between dif-
ferent players in biological or pharmacological sys-
tems, without any numerical information to inform on 
the frequency, extent, or rate of those interactions. 
Even in cases when the model is more quantitative, its 
parameter values, including units and uncertainty esti-
mates, are often omitted from the publication or scat-
tered inconsistently over text and figures. When those 
parameters are reported, the data, knowledge, and 
assumptions that underwrite their values are often 
missing or their adequacy, quality, and quantity are 
poorly discussed.
3. The paper in which the model is published provides 
its description but fails to provide the associated 
model file or programming code. The emergence of 
standardized markup languages (SBML),16 such as 
systems biology markup language,9 cell markup lan-
guage (CellML),5 pharmacometrics markup language 
PharmML,17 or model description language (MDL),18 
the existence of fully compatible modeling software 
(e.g., COPASI,19 SimBiology20), and the availability of 
open source tools to translate between them (e.g., 
Systems Biology Workbench21) should enable and 
encourage researchers to share their encoded 
model. However, although the provision of model 
files or computer code is encouraged by several 
scholarly journals, in practice some scientists are re-
luctant to give up their competitive advantage over 
other research groups. Some authors provide a high-
level description of the model to communicate their 
findings without necessarily including sufficient in-
formation to allow others to reproduce their findings. 
4. The model file or code is provided, but it is not prop-
erly documented. Sometimes the code is inade-
quately annotated, incorrectly encoded, lacks a 
complete set of initial conditions or parameters, or 
does not correspond to the accompanying model 
description, all of which prevents any further modifi-
cations, expansions, or reductions by a different re-
search group.
5. The model behavior does not correspond to what is 
presented in the paper. The simulations or analyses 
that are reported in the article cannot be reproduced 
with the governing equations and/or the simulation 
code provided. Model repositories such as BioModels4 
are trying to address this issue through a systematic 
curation process, for example, checking whether it is 
compliant with the Minimum Information Requested 
in the Annotation of Biochemical Models (MIRIAM) 
guidelines.22 This curation focuses on the correspond-
ence of an encoded model to its associated reference 
description. However, it is not exhaustive for each 
paper, and it is limited to only a fraction of the public 
model space, largely because of the lack of the ade-
quate documentation in the papers.
6. The impact of the model is overstated. In those cases 
where the modeling results can be reproduced, often 
the outcome does not inform the initial question(s) 
posed or has not been contrasted with experimental 
results or the authors extrapolate it to cases that are 
Figure 1 Annual number of PubMed abstracts containing the 
term “systems pharmacology” since the year 2000.
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out of the model scope. Frequently the model appears 
to be a post hoc analysis of a data set rather than a 
novel analysis driven by a scientific question. This 
sheds significant doubt on whether the model is a 
good starting point for further decision making or 
model development. This is probably one of the most 
important challenges within the regulatory context.
The overall result from this state of affairs is a general lack 
of confidence in the models which coupled with their per-
ceived highly technical nature, can undermine the trust that 
the bench- based community and decision makers may have 
in QSP as a discipline. This situation also implies the need 
for a significant use of resources (industrial and academic, 
time-and cost-wise) in trying to implement, reapply, or further 
develop models of questionable reproducibility and/or reus-
ability. This in turn has a negative impact on the innovation 
trigger phase of the Gartner Hype Cycle for QSP.
The aim of this article is to present and discuss a mini-
mum set of recommendations that can enhance the qual-
ity, reproducibility, and further applicability of QSP models. 
This document summarizes the outcomes of a discussion 
held among academic and industrial members of the UK 
Quantitative and Systems Pharmacology Network (UK 
QSP Network).23 This network was created in 2015 by a 
group of UK and international scientists in industry and ac-
ademia to bring QSP to the forefront of UK research space 
and nurture its growth. The network is jointly funded by 
the Engineering and Physical Sciences Research Council 
(EPSRC)24 and the Medical Research Council (MRC)25 in 
the United Kingdom.
These recommendations focus on the issue of how to 
document QSP models when published, framing a check-
list of minimal requirements. Discussions about models’ 
 accessibility, exchange mechanisms, archiving, software, 
and visualization or coding language are out of scope for 
this article.
A number of publications have recently proposed guide-
lines or recommendations on modeling practices. Some 
of these focus on the design process of QSP models,26–28 
whereas others suggest methods for assessing the quality 
and/or adequacy of QSP models in particular27,28 or models 
that support the MID3 paradigm in general.29 If physiologi-
cally-based pharmacokinetic (PBPK) models are considered 
a special case of QSP modeling, then it is important to also 
mention the recent efforts by both the European Medicines 
Agency (EMA)30,31 and the FDA.22,32 
PURPOSE AND CONTEXT OF THE MODEL
When developing a computational model, the following 
two overriding questions need to be asked: “Do I need 
a model?” and “What is the purpose of the model?” It 
is tempting to become too involved in the details of the 
structure and implementation of a model early on in the 
modeling process. However, careful thought needs to be 
given to the aims of developing the model and, crucially, 
to the biological or biomedical questions that it should 
answer. Stepping back and asking these questions is im-
portant because they require the modeler to think carefully 
about the operational approach that will be taken, what 
data might be needed, which assumptions might have to 
be considered and critically, and what hypotheses will be 
tested. Models offer the possibility to explore relatively 
quickly scalable “what if” questions, serving as an extra 
component in the toolbox of the bench scientist to opti-
mize their experimental procedures, thus saving time and 
resources on experiments that may prove unproductive. 
A good example of this is the use of models to reduce, 
refine, or replace (the “3Rs”)33 certain types of preclin-
ical experiments. At the point of publication, the spe-
cific question that the model was developed to answer 
and/or the hypothesis that it was built to test should be 
clearly stated (e.g., “We tested the hypothesis that neg-
ative regulation of Syk protein phosphorylation by Tula2 
leads to periodic (oscillatory) time dependent solutions”). 
Clarifying this information will enable potential end users 
of the model to determine whether it is suitable or not for 
their own objectives, and in the latter case, how much 
effort it would take to modify it and make it fit for purpose.
To address this component of the modeling process, a 
critical aspect to success is the inclusion of stakeholders 
in the development of the model. Gadkar et al.28 already 
refer to this important step in the development of systems 
pharmacology models. There are usually two types of 
stakeholders in the process who provide different types 
of input.
The first type of stakeholder is the “end user.” This 
 person will be making use of the model simulations or anal-
yses to gain insights into the system under study, optimize 
the experimental protocol, inform his or her own work, or 
drive decision making (including regulatory submissions). 
The end user is able to provide the appropriate context for 
the model and, as with any project that involves delivery 
of a “product” to an intended user, he or she should be 
consulted at various points during the development of the 
model. By defining the context, this stakeholder allows for 
the precise distillation of the questions to be asked of the 
model. In addition, an idea of the impact that the model-
ing exercise will have should be provided in terms of the 
strategic go/no- go decision making, time reduction and/
or economical costs, or societal benefit. The following 
is a good question to ask to elicit this information from 
the stakeholder: “What will happen if we don’t build this 
model?”
The second type of stakeholder is the “domain expert.” 
This person can assist the modeler in understanding the 
mechanistic aspects of the system that is being modeled. 
Often what is modeled is complex and requires specific 
knowledge to help understand what is known and, criti-
cally, what is unknown about the system. This interaction 
helps to identify the assumptions that are needed or new 
data that may need to be found to create a model that is an 
appropriate abstraction and representation of the system 
under study. During this time, it is essential that a shared 
understanding of the terms used in the process is agreed 
on, as often the same word can be interpreted differently 
by different people. Sometimes the “end user” and the 
“domain expert” are one and the same person. Because 
domain expert knowledge can come from a variety of 
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sources and elicitation approaches, consideration should 
be given to how this prior knowledge has been handled 
and combined (e.g., through a Bayesian approach as pre-
sented by Weber and Koch34,35 in an EMA public workshop 
on the extrapolation of efficacy and safety in medicine 
development).
As proposed by Timmis et al.,26 QSP modelers could elicit 
and document the stakeholders’ input by borrowing a meth-
odology from the area of safety engineering to develop ro-
bust argumentation structures. In his presentation of a model 
qualification method (MQM©) for mechanistic physiological 
models, Friedrich29 presents a series of questions that could 
potentially apply to more general QSP model development 
and lead the conversations between modelers and their 
stakeholders. These could be complemented by the set of 
example questions summarized in Table 1 in the Peterson 
and Riggs publication11 about the impact of QSP on the reg-
ulatory domain.
The justification of the type of modeling approach se-
lected and the way it has been implemented should be 
derived from the questions and context provided by the 
stakeholders. Modelers can easily tend to favor those 
methodologies with which they are most experienced 
and comfortable instead of evaluating which approach 
is most adequate, such as algorithmic or mathematical, 
based on ordinary or on partial differential equations, de-
terministic or stochastic, or a  hybrid between different 
methods. If this choice is not properly considered, then 
the model may not provide useful and/or correct answers. 
In their article on QSP design and estimation methodolo-
gies, Ribba et al.27 describe a good example of how the 
need for a QSP model arises from a question that can-
not be solved by standard modeling approaches, such 
as empirical pharmacokinetic/pharmacodynamic (PKPD) 
modeling.
All of the information gathered during these initial phases 
of the modeling process should be communicated in a 
transparent way in the resulting publication, from a clear 
formulation of the questions addressed to their context, ex-
pected impact, and the reasons behind selecting a particular 
technical approach.
MODEL STRUCTURE AND MODELING 
METHODOLOGY
After defining the purpose and context of the model comes 
the model- building phase. A few initial decisions are made 
regarding the model structure and methodology, which 
do not require the use of experimental data. This section 
proposes good practice guidelines when reporting these 
decisions, which include the choice of model domain, 
structure, scale, modeling method, and software. The term 
“modeling” refers to both mathematical and computa-
tional modeling unless otherwise stated. The term “devel-
opment” infers the symbolic formulation of a mathematical 
model or the algorithmic articulation of a computational 
model.
1. The model domain and general structure. The  domain 
to which a model is to be applied should be clearly 
stated in the introduction to any work, as it influ-
ences other aspects of the modeling process such 
as model formulation and assumptions.28 “Domain” 
may have different contextual meanings. For example, 
it may represent (i) a therapeutic area (e.g., neuro-
degeneration, oncology, etc.), (ii) biological scales 
(organ/tissue level, cellular level, intracellular level, 
or multiscale), or (iii) a specific system to which the 
model applies (e.g., mammalian cells, a severe asthma 
patient, etc.). The model purpose, as defined in the 
previous section, plays a significant role in deter-
mining the model domain and in explaining it to 
other model developers and users. In addition, the 
biological knowledge elicited from stakeholders 
Table 1 Mock example of good practice in parameter value reporting in tabular form 
Name Definition Value Units Source Details
k Second- order rate constant of 
degradation of the inactive form upon 
interaction with the active form
1 (μM hour)−1 Smith et al. 
(2002)
The rate constant governing the interaction 
between the active and inactive proteins is 
reported to be in the order of 278 M−1 s−1 for this 
class of proteins
α First- order rate constant of inactive 
protein decay
0.2 hour−1 Doe et al. 
(2017)
Table 3 shows the half- life values measured for 
inactive proteins. We took the geometric mean of 
those values and derived the rate constant with 
the expression α = ln(2)/half- life
β Zero- order synthesis rate of the inactive 
protein
0.5 μM/hour Derived At steady state, β = a[α–kb] = 5[0.2–1.0.1] = 0.5
γ Zero- order synthesis rate of active 
protein
0.005 μM/hour Derived At steady state, γ = δb = 0.05·0.1 = 0.005
δ First- order rate constant of active protein 
decay
0.05 hour−1 Boggs et al. 
(1990)
Calculated from Figure 3 in the reference
A
0
Initial concentration of inactive protein 5 μM Grundy 
(2004)
Assumed equivalent to the average concentration 
of unphosphorylated Syk in untreated cells
B0 Initial concentration of active protein 0.1 μM Plakket 
et al. 
(2000)
Approximated from the average total of phospho-
rylated and unphosphorylated ERK, assuming 
the active protein correlates with that of 
phosphorylated ERK
ERK: extracellular signal-regulated kinase; Syk: spleen tyrosine kinase.
5www.psp-journal.com
Best Practices for QSP Models
Cucurull- Sanchez et al.
determines how all of the different components of 
the model are connected. The domain and general 
structure of the model should be made clear to 
the reader by using some form of schematic rep-
resentation (see an example in Figure 2), showing 
the most significant elements of the model, such 
as compartments, species, processes, feedback 
loops, modules, submodules, and so on. Currently, 
several open source and commercial software pack-
ages provide tools to produce visualizations of the 
model structure. Whenever possible and appropriate, 
it is recommended to follow some sort of standard 
graphical notation, such as the systems biology 
graphical notation (SBGN), to facilitate the reader’s 
comprehension.36
2. Model formulation or algorithm. These recommenda-
tions depend on whether the method selected is 
mathematical (e.g., system of ordinary differential 
equations) or computational (e.g., agent-based 
models). For mathematical models, the formulation 
of the model needs to be correctly stated using rel-
evant notation and explanations. All dependent and 
independent variables need to be accompanied by 
written descriptions (e.g., “Here x(t) represents the 
total concentration of the metabolite, and t is time”), 
with explicit statements of dependencies, for exam-
ple, on time. All equations need to be clearly dis-
played on the page with relevant boundary and/or 
initial conditions stated. The mathematical domain of 
problem definition also ought to be stated (e.g., 
“∀t > 0”). A written explanation of each term in the 
equation should be given either before or after the 
stated mathematical formulation and/or overarching 
explanations of the biological or pharmacological 
meaning of each term stated (see Box 1 for an exam-
ple). This should include any abstractions and/or 
simplifications made. In the case of a computational 
model, all of the above applies to any equations 
Figure 2 Example of good practice in model structure visualization.  
Box 1 Example of good practice in mathematical formulation
The interaction between the inactive protein A(t) and its active form B(t) is given by the following governing equations:
dA
dt
=
Inactive protein production
⏞ ⏞
β −
Inactive protein degradation via active form
⏞ ⏞
kAB −
Inactive protein decay
⏞ ⏞
αA ,
dB
dt
=
Active protein production
⏞ ⏞
γ −
Active protein decay
⏞ ⏞
δB ∀t>0,
with the initial conditions A(0) = A
0
 μM and B(0) = B μM, where t represents time in hours. Here k is the reaction rate 
constant in (hour μM)−1 units representing the rate at which the degradation of 1 μM of inactive protein (A) is triggered 
by its interaction with 1 μM of the active protein (B), α is the rate constant of inactive protein decay (hour−1), β is the 
production rate of the inactive protein (μM/hour), γ is that of the active protein (μM/hour), and δ is the rate constant of 
active protein decay (hour−1).
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associated to the algorithm, and the latter needs to 
be clearly stated using pseudo-code. For instance, 
in the case of an agent-based or cellular automata 
model, the definitions of all parameters and rules de-
scribing how each individual element of the model 
behaves need to be indicated. The transition be-
tween each state at each given temporal point or 
spatial point needs to be made clear (e.g., “individu-
als move between proliferative and apoptotic states 
at probabilistic rates selected randomly from a uni-
form distribution”), including the condition that trig-
gers each transition (e.g., “where the selected rate is 
less than 0.5”).26 In both mathematical and computa-
tional models, all definitions need to include a cor-
rect statement of the parameter units (generally from 
the International System of Units), their value (or 
range of values, if variability is considered), and 
source (for further details, see the “Input Data, 
Knowledge, and Assumptions Going Into the Model” 
section). Where space and word limitations do not 
allow for this information to be in the article main 
text, it can be provided as supplementary materials.
3. Model solving and simulation method. For mathemati-
cal models consisting of differential equations, these 
need to include a statement on the algorithm used to 
solve the governing equations and the value of algo-
rithm-relevant parameters for doing so (e.g., “The gov-
erning ordinary differential equations were solved 
using the Runge-Kutta fourth/fifth order method im-
plemented via the ode45 solver in MATLAB®.  The rel-
ative tolerance was set at 1 × 10−6”). The type of 
machine, platform, and, where applicable, package 
used to solve the equations needs to be stated (e.g., 
“The governing equations were solved using MATLAB 
version 2017a on an Apple iMac desktop running 
macOS Sierra Version 10.12.6”). The steps used by a 
computational model algorithm need to be made clear. 
Where models are considerably complex, pseudo-
code outlining the main steps should be generated, 
ideally via a schematic diagram or plan.
4. Code files. The recommendation is to make available to 
other users the code and/or model files generated to 
build and solve the models. This can be done in several 
ways, ideally by depositing them in online model re-
positories such as BioModels,4 CellML,5 or DDMore,6 
which provide a platform for easy model search and 
retrieval. Other ways to share models include the provi-
sion as supplementary material of scientific articles, 
the uploading of copies to academic author websites, 
and the sharing on public platforms for computational 
code such as GitHub.37 The best approach is to en-
code a model in standard formats when possible (e.g., 
SBML,9 CellML,38 PharmML,17 or MDL18 in the case of 
ordinary differential equation systems), as they allow 
interoperability.16 The code should be easy to follow, 
annotated and as error free as possible. Ulterior users 
should check it for consistency before using it, and it 
would be in the best interest of the modeling commu-
nity to report any errors found to a designated member 
of the research team (e.g., corresponding author) or to 
the curators of the model repository. Future mainte-
nance and the upgrading of the code by the original 
authors should not be a stipulation of it being depos-
ited in repositories.
INPUT DATA, KNOWLEDGE, AND ASSUMPTIONS 
GOING INTO THE MODEL
Once the model structure and methodology have been de-
fined and justified, the model then needs to be connected 
with experimental observations for it to fulfil its purpose. 
This means, first, informing the variables and parameters 
in the model with specific values in a process that is gen-
erally known as “model parameterization”. Second, ex-
perimental data are required to gain an idea of the quality 
of the performance of the model by comparing it to the 
known behavior of the biological system. This section 
deals specifically with the former aspect of experimental 
data usage.
The reproducibility of modeling results depends on the 
specific parameter values used, thus the reporting of those 
values, how they were determined, and the source of in-
formation for doing so is of high importance. A parameter 
description (most often in tabular form; see an example in 
Table 1) should be supplied, including the symbol or name 
representing the parameter, its definition, value, units, and 
the sources used to determine it. Details of how the param-
eter value was obtained need to be reported, specifically 
where parameter values have been derived as functions 
of other parameters not included in the model or by fitting 
model simulations to experimental data. Such parameter 
estimations usually yield statistical information related to 
parameter precision (importantly, not accuracy) such as 
standard errors or correlation matrices, and sometimes in-
formation derived from more sophisticated approaches such 
as profile likelihood.39 All of this information could be added 
to the parameter table and/or in an annex (e.g., “Parameter 
values were first determined by assuming equal rates of ab-
sorption and excretion. These were then varied to obtain a 
least- squares fit between the model and the patient cyto-
kine levels reported by Smith et al. The parameter values 
reported are those that gave the minimal error residuals”). 
It is important to note that the concept of “parameter” here 
is used in its widest meaning and includes scalars such as 
compartmental volumes as well as amounts or concentra-
tions of the interacting species in the system at steady state 
or at initial conditions.
Input data can come from a variety of sources. It can be 
extracted from public or in- house literature or databases, 
obtained from a personal communication (which ideally 
should be referenced), or from experiments specifically 
designed to inform one (or a subset) of the processes rep-
resented in the model. Data can also come in a variety 
of types, including kinetic or thermodynamic constants 
measured in vitro or ex vivo, physiological parameters, 
biomarker clinical data at pretreatment or from longitudi-
nal studies (including - omics data), drug pharmacokinetic 
profiles or parameters (fitted or allometrically scaled from 
in vivo parameters), and drug safety end points. Whatever 
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the source and form of the data, details of the key ques-
tions that drove the experiment and the experimental con-
ditions should be explicit and relevant to the system being 
modeled. Limitations of the data, such as known errors, 
outliers, high variability, or decisions on the removal of 
particular data points or data sets, should also be stated. 
Input data can be provided along with the code file as sup-
plementary information or as a reference to a repository for 
unstructured data such as BioStudies.40
Knowledge in the context of QSP model parameterization 
refers to the qualitative and/or semiquantitative information 
that the scientific community in general and the modeler 
stakeholders hold about the expected behavior of the 
model or the biological processes described therein. For 
example, a certain marker of drug activity may be known 
to reach a peak after about 3 hours of treatment and de-
cline to baseline levels after 12 hours, but no explicit data 
set is available to fit the model parameters describing that 
activity.
Assumptions come into play when there is not enough 
data available to parameterize the model and existing 
knowledge about the system is insufficient to inform pa-
rameterization or to reduce the number of parameters. 
The setting, testing, and evaluation of model assump-
tions have been previously referred to and described in 
the context of the MID3 paradigm.41 They have been di-
vided into the following six distinct types of assumptions: 
pharmacological, physiological, disease, data, mathe-
matical, and statistical. Assumptions are scoped by what 
the model is intended for (e.g., to understand process 
relationships, to simulate the effect of different scenarios 
on pharmacological events), as discussed in the previ-
ous section. Care should be taken to keep the number 
of assumptions as low as possible because an increase 
in the number and complexity of modeling assumptions 
can lead to higher uncertainty and risk around modeling 
results. The level of evaluation and testing of the assump-
tions (e.g., by sensitivity analysis, discussed in the next 
section) needs to be tailored accordingly. This is a key 
aspect in the selection of the right level of granularity in 
a QSP model which, as Ribba et al.27 point out, is one 
of the most difficult decisions during the QSP modeling 
process.
Careful documentation of the collation of sources and 
usage of input data, knowledge, and assumptions made 
in formulating and informing a model increases the confi-
dence in its results. It acts to ensure that quality assurance 
and quality control of the developed model have been un-
dertaken.41,42 A discussion of the potential limitations of 
the model in the context of the available data, knowledge, 
and assumptions also constitutes good practice because it 
allows modeling practitioners to reuse or extend the QSP 
model with new or expanded information.
MODEL VERIFICATION
The definition of model verification in the literature is rather 
unresolved. Some authors describe model verification as 
the part of a model qualification process that focuses on 
the correctness of the mathematical model structure.31 
They understand model qualification as a broad activity 
aimed at establishing confidence in the model to simulate a 
certain scenario in a specific context and showing its ability 
to predict with a certain purpose. Model qualification has 
also been described as an approach to determine whether 
a model is fit for purpose.29 On the other hand, other au-
thors30,32,43,44 define verification as the process of model 
testing with a data set that has not been used for initial 
model building, often part of a verification/modification it-
erative process of model refinement prior to its application. 
Here, we refer to model verification as the process in which 
the modeler determines the degree of self- consistency and 
robustness of the model prior to assessing its performance 
against experimental observations.43,45
At the very least, computational and mathematical mod-
els solved numerically should have their code tested for 
consistency. Such testing consists of ensuring the software 
code does not contain any coding errors (e.g., bona fide 
mistakes or additionally coded terms not included in the 
original formulation/statement) and checking that the solu-
tions to known results or limit conditions of the model (e.g., 
A  +  B Ǌ C yield no C when A or B are zero) are correctly 
produced. Such testing can greatly alleviate the likelihood of 
undertaking experimental work based on model predictions 
that are later found to be incorrect.
In addition, mathematical and statistical analyses can help 
us understand the range of applicability of a QSP model; 
it provides tools to allow us to explore behavior for which 
there is a lack of data. In fact, the analysis of any model is 
important in identifying a system’s overall behavior. Such an 
analysis can highlight aspects not previously conceived or 
considered and help provide a comprehensive understand-
ing of the system dynamics. The reporting of the mathe-
matical analyses of a model should include the methods of 
analysis used and outline the main steps required to repro-
duce the results. These results should be clearly stated and 
their meaning placed in the context of the overall  problem/
application considered.
There are certain key tests and analyses for QSP mod-
els that should be considered when performing model ver-
ification. One of them is structural identifiability analysis, 
which can help determine whether the model structure and 
parameter estimates inferred from the known or assumed 
properties of a system are suitable. This can help determine 
whether increasing the quality of the input data set used for 
parameter estimation (see the previous section) would help 
reduce uncertainty in the estimation, the uncertainty may 
stem from a poor model structure. This analysis considers 
the uniqueness (or otherwise) of the unknown model pa-
rameters from the input- output structure corresponding to 
experiments proposed to collect data for parameter estima-
tion. Such an a priori analysis applies under an assumption 
of the availability of perfect, noise- free observations. This is 
an important but often overlooked theoretical prerequisite 
to experiment design, system identification, and parameter 
estimation because estimates for unidentifiable parameters 
are effectively meaningless. If parameter estimates are to be 
used to inform about intervention or inhibition strategies or 
other critical decisions, then it is essential that the param-
eters be uniquely identifiable or otherwise supported from 
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independent, reliable information. This is particularly true if 
the model potentially may incorporate many unknown model 
parameters with relatively few model outputs. Numerous 
techniques for performing a structural identifiability anal-
ysis on linear parametric models exist, and this is a well- 
understood topic.46–48 In comparison, there are relatively 
few techniques available for nonlinear systems, and sig-
nificant (symbolic) computational problems can arise, even 
for relatively simple models.49–51 During the past few years, 
software packages have been developed and are generally 
widely available that can ease the burden in performing such 
analysis.52–55 These include (and are not limited to) struc-
tural identifiability analysis software using the exact arith-
metic rank approach (EAR),56 StrikeGoldd2,57 COMBOS,58 
DAISY,59 and Profile Likelihood.39 In addition, there are also 
techniques available in the literature60,61 to establish model 
parameter redundancy, which alongside structural iden-
tifiability analysis can support model reparameterization 
or lumping, should this be required.62 The introduction of 
recent techniques for the structural identifiability analysis 
of mixed- effects models (commonly applied in a popula-
tion PKPD context) widens the scope of the application of 
such analysis to QSP models.54 With the availability of such 
tools, there should be an expectation that a certain level of 
structural identifiability analysis of QSP models should be 
performed and reported as a prerequisite to parameter esti-
mation and as a component of experiment design.
In the case of dynamical mathematical models (e.g., dif-
ferential equations), one should also seek to determine the 
steady states of the system. In a QSP model, these should 
include the steady states in absence of drug. This allows two 
things to be achieved. First, such analysis acts as a consis-
tency check—is the model reproducing the baseline state? If 
not, is the model then correctly formulated? Second, it allows 
for a basic understanding of the system to be obtained. If 
multiple steady states are found, then changes in the param-
eters can lead to changes in the stability or even existence 
of these steady states, which can lead to dramatic changes 
in the overall dynamics of the model. A bifurcation analysis 
determines those curves in the parameter space at which 
such changes occur. If certain dynamics are not biologically 
feasible, then this gives bounds on the feasible parameter 
regions and thus helps determine when an extrapolation is 
likely to work and when it is probably going to fail. In ad-
dition, such an analysis can also aid parameter estimation. 
If such transitions have been observed experimentally, this 
can provide an implicit method to determine unknown pa-
rameters. For small- scale models (e.g., four governing dif-
ferential equations or fewer), such an analysis can generally 
be achieved analytically. For larger scale systems, such work 
can be undertaken using mathematical computer packages 
such as Maple,63 MATLAB®,64 and DsTool.65 Model reduc-
tion methods should also be considered as a means of gain-
ing further understanding of the system.66
Computational analysis of mathematical models should 
also be undertaken as a complement to the above analysis 
techniques or where such mathematical analysis is not possi-
ble. At the very least, the analysis of dynamic models (mathe-
matical or computational) should include a sensitivity analysis. 
Sensitivity analysis is commonly applied to parameterized 
models to establish those parameters that are most sensitive 
to perturbation and those that have the most effect on model 
responses when perturbed. Formal sensitivity has long been 
considered an important aspect of PKPD modeling (see, for 
example, Nestorov et al.67,68). Kirouac69 even suggests a 
methodology, underpinned by sensitivity analysis approaches, 
that could become a means to quantifying qualitative QSP 
simulation results, placing this technique in the realm of model 
“validation.” Clearly such an analysis is also a key component 
in the modeling of QSP systems, and with techniques such 
as generalized sensitivity functions, should be a fundamental 
component in QSP modeling.70 Indeed, a growing number of 
journals require such analysis be undertaken before a manu-
script is accepted for publication.
The robustness of model simulations to input perturbations 
should also be considered, potentially including μ- analysis, 
an approach to quantifying the effects of parameter uncer-
tainty as applied to models in systems biology, for example, 
to ascertain the extent of applicability of the models gener-
ated.71 This may also be performed in a statistical context.
However, there will always be uncertainties in the parame-
ter estimates even if the model is structurally identifiable and 
the quality and quantity of the experimental data are rela-
tively high. The combined effects of dynamical model analy-
sis (analytical and computational) and identifiability analysis 
can be greatly informative in assisting the design of further 
experiments to inform on unidentifiable parameters and their 
values without the need for a reduction of the model and 
thus loss of descriptive power. As well as this, an approach 
to further strengthen the plausibility of the model simulations 
is to use experimental data to validate the model.
MODEL VALIDATION
We refer to model validation as the process in which the 
modeler determines the degree to which the model is an 
accurate representation of the real world43,45 using exper-
imental observations that have not been used as input to 
estimate the model parameters.
In the context of QSP, this is equivalent to running a mul-
tiscale simulation of the model, where emerging properties 
of the whole or of a submodule of the model are compared 
with the behavior observed experimentally for that model or 
submodule. The validation of individual model submodules 
(e.g., the cell cycle of eosinophils in the human body, or the 
absorption, distribution, metabolism and excretion (ADME) 
cycle that a drug undergoes in a healthy volunteer) adds 
confidence in the parameter values for those submodules, 
whereas the validation of the whole model high- level behav-
ior (e.g., the forced expiratory volume in 1 second (FEV1) 
response in asthmatic patients under a specific drug treat-
ment) adds confidence on how those submodels were inte-
grated with each other and within the framework of human 
physiology. The latter is also the ultimate measure of credi-
bility of the simulations that will address the specific ques-
tions posed initially by the modeler. 
As mentioned in the “Input Data, Knowledge, and 
Assumptions Going Into the Model” section, experi-
mental observations can consist in data or in knowl-
edge about the behavior of the biological system. Where 
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quantitative data are available to assess the degree of 
performance of the model, this should be utilized. When 
no quantitative data are available, qualitative data and/
or “expert” stakeholder knowledge of the system trends 
can be applied, for example, to rule out certain hypoth-
eses about the intrinsic behavior of the system. In either 
case, at the point of publication, the data or knowledge 
used to validate the model should be clearly referenced 
and described and its relevance to the model context ad-
equately explained. Lu et al.,72 Kanodia et al.,73 Ortega 
et al.,74 Karelina et al.,75 and Peterson and Riggs,76 to 
name some examples, illustrate well the validation of a 
model and its reporting.
The modeler should aspire to produce plots of simula-
tions and overlay the experimental data onto these, includ-
ing any measures of their potential and perceived variability 
(i.e., standard error bars or 95% confidence intervals around 
the experimental data, shadows from ensemble simulations, 
etc.) whenever possible. As more data sets and increasingly 
diverse contexts and types of perturbations are compared 
with the model simulations, the more opportunities arise to 
learn about the domain of applicability of the model. The 
term “learn” here is substantially important—models are 
not only useful for their potential to predict the system be-
havior but also essentially for consolidating the knowledge 
and assumptions that exist about the system. A disagree-
ment between simulations and experimental observations, 
assuming experimental observations can be considered to 
be directly pertinent, highlights the fact that one or some 
of the underlying assumptions in the model are incorrect.77 
Thus, the model structure and/or its parameter values need 
to be reconsidered and potentially new experimental assays 
designed to fully understand from where the disagreement 
stems. Often, the trends in residual analysis, or qualitative 
features of the simulation, can help spot those assumptions 
that are potentially incorrect. Once those disagreements 
have been minimized or when the specific situations where 
those disagreements appear have been clearly identified, 
then confidence in the model simulations, the underlying 
assumptions, and the overall credibility of the model will 
increase.
Model quality tests usually run in the context of other in 
silico simulations, such as Akaike’s information criterion, 
Bayesian information criterion, R2, Q2, and so on may be in-
adequate here because the goal of QSP models is not to ob-
tain a highly precise estimate of the system readouts (e.g., 
biomarker levels changes), but to obtain a ballpark estimate 
with the limited knowledge that there is of the system com-
ponents, of what can be expected when all of those compo-
nents are put together.78
Ultimately, the validation of the model ought to be per-
formed in the strictest sense of the term validation: this is 
when the data available to test the model performance have 
been generated in an experiment designed on the basis of 
the model simulations. However, it is unusual at the time of 
publishing the model for the modelers to count on these 
data, so normally the reporting of the modeling exercise fin-
ishes with the application of the validated model to resolve 
those questions posed by the “end user” stakeholders.
MODEL RESULTS, APPLICATION, AND IMPACT
Once the model has been developed and has reached a 
satisfactory degree of maturity and performance, it can 
then be applied to answer the questions originally posed. 
The degree to which the model can answer those questions 
and the answers themselves will determine its impact.
The answers normally rely on some sort of graphical rep-
resentation of the model simulations and on the capture of 
the outcome values of key system elements (e.g., regarding 
molecular species, cell types, system agents, clinical bio-
markers, etc.) during and at the end of those simulations. 
All of these data, graphical or numerical, should be reported 
clearly as well as the model conditions in which those sim-
ulations were run, including initial conditions and simulation 
time.
The impact of the model is primarily measured in relation 
to the original purpose of the modeling exercise, that is, the 
questions posed and the anticipated output. The impact, 
including its type and extent, will be viewed differently in 
different types of environments (academic, industry, or reg-
ulatory) and by different types of roles (bioscientist, medic, 
pharmacologist, chemist, practitioner, manager, director). It 
is for this reason that regulatory vs. industry criteria for im-
pact have been developed.41,79
With respect to direct impact within our original list 
of stakeholders, for the “end user” the impact will be 
judged by whether key questions have been addressed 
and whether the model can be easily interrogated to an-
swer emerging questions. For the “domain expert”, judg-
ment may well be based on whether the model “sensibly” 
encodes biological knowledge. The assessment of the 
model’s impact by the modelers will be partly based on 
feedback from the stakeholders, but direct impact will 
depend on whether the modeling exercise has provided 
a reusable model and a deeper understanding of how to 
model a particular aspect of biology and pharmacology. It 
is important to note that the perception of added value that 
the “end user” stakeholder has of the modeling exercise is 
instrumental in achieving and measuring impact beyond 
the initial circle of influence.
Regarding the knowledge acquired, the value added by 
the QSP model could be the following:
1. A positive new discovery: the model allows the ex-
ploration of untested contexts, so it could become 
a source of new (ranges of) parameter values (e.g., 
“what is the required potency for the new drug?”) 
or of a completely new hypothesis (e.g., “what if 
we test this new dosing regimen?” as was the case 
with the rhPTH filing11).
2. A confirmation: the model may not venture into extrap-
olating to untested contexts, but because of its integra-
tive, bottom-up nature, QSP provides unique insights 
that are unavailable through alternative modeling tech-
niques, so it becomes a sandpit where existing data 
can be interpreted in data-rich contexts or where un-
certainty can be explored and delimited in data-poor 
contexts, enabling better informed decisions.
10
CPT: Pharmacometrics & Systems Pharmacology
Best Practices for QSP Models
Cucurull- Sanchez et al.
Table 2 Abbreviated list of recommendations on best practice to maximize the use and reuse of QSP models 
QSP workflow step
Recommendations
Relevant referencesMathematical Computational
1. Purpose and context of the 
model
• Ask “Do I need a model?” and “What is the purpose of the model?”
• Engage with stakeholders: “end users” and “domain experts”
• Formulate clearly the questions addressed, their context, expected impact of 
the decisions derived from the model, and rationale for the selection of QSP as 
modeling methodology
Peterson & Riggs (2015)11
Timmis et al. (2017)26
Ribba et al. (2017)27
Gadkar et al. (2016)28
Friedrich (2016)29
2. Model 
structure and 
modeling 
methodology
i. Model domain 
and general 
structure
• Define clearly the model domain: therapeutic area, biological scale, biological/
clinical system
• Provide a schematic representation of the model domain and general structure 
(e.g., Figure 2)
• Whenever possible, follow standard graphical notation (e.g., SBGN)
Gadkar et al. (2016)28
Figure 2
Le Novère et al. (2009)36
ii. Model 
formulation or 
algorithm
• Provide all equations and boundary conditions 
(e.g., Box 1)
• Explain all the terms and their biological/
pharmacological meaning
• Clearly state the 
algorithm using 
pseudo-code and 
clearly state any 
associated equations
• Explain all the rules and 
parameters and their 
biological/pharmaco-
logical meaning
Box 1
Timmis et al. (2017)26
• Explain any abstractions and/or simplifications made
• Report units for each element in the model
iii. Model solving 
and simulation 
method
• State the method used to solve the system of 
equations (e.g., Runge-Kutta fourth/fifth order 
implemented via the ode45 solver in MATLAB
64) 
• Provide absolute/relative tolerance value
• Clearly state simulation 
engine used (and 
version)
Timmis et al. (2017)26
• Provide software package used and version
iv. Code files • Share code and model files generated to build and run the model via the 
following: 
ǫ Supplementary material of an article
ǫ Public online model repositories (e.g., BioModels4, DDMore6)
ǫ Academic author websites, or
ǫ Public platforms for computational code (e.g., GitHub37)
• Ensure code is easy to follow, adequately annotated, and as error free as 
possible
• Whenever possible, use a standard format (e.g., SBML, PharmML)
Chelliah et al. (2015)4
Lloyd et al. (2008)5
DDMore- Foundation 
(2012–2018)6
GitHub (2018)37
Hucka et al. (2003)9
Golebiewski (2019)16
Swat et al. (2015)17
Smith et al. (2017)18
Cuellar et al. (2003)38
3. Input data, knowledge and 
assumptions going into the model
• Use input data from systems under experimental conditions as relevant as 
possible to the system being modeled
• Provide a detailed model parameter description, including the following: 
ǫ Symbol/name of parameter
ǫ Definition
ǫ Parameter value (or range of values)
ǫ Units
ǫ Sources used to obtain it (literature citation, database, derivation from other 
parameters, experiment presented in the same report/article, in silico 
estimations, etc.)
ǫ Details of how the parameter value was determined (measured directly, fitted 
or assumed) and whether the underlying data has any limitations (suspected 
errors, outliers, high variability, excluded data points, etc.)
• Consider using a tabular format to present this information (e.g., Table 1)
• Consider providing actual data files along with code files (see 2. Model structure 
and modeling methodology, iv. Code files in this table)
• Describe the following in detail: 
ǫ Qualitative and/or semiquantitative knowledge obtained firsthand from 
stakeholders
ǫ Assumptions (pharmacological, physiological, disease, data, mathematical, 
statistical) and how they were tested
• Discuss potential limitations of model in the context of available input data, 
knowledge, and assumptions
Table 1
Sarkans et al. (2018)40
Marshall et al. (2016)41
Ribba et al. (2017)27
Bonate et al. (2012)42
(Continues)
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3. A realization of a misconception: when a modification 
of model assumptions is required to describe experi-
mental data, this points to a gap in biological knowl-
edge (e.g., “our current understanding of the drug 
target biology does not explain the observed in vitro 
phenomena quantitatively”), which generates a revision 
of the initial hypothesis; the QSP model can then help 
identify the key questions needed to expand our knowl-
edge sufficiently and design the studies required to in-
form them.77
The type of decision making that is affected by this 
knowledge will depend on the specific environment where 
the decision is made. In a pharmaceutical business, the 
knowledge acquired could translate into, for example, 
stopping or starting a project, seeking the reoptimization 
of certain candidate drug properties, or redesigning an 
experiment or clinical study. A good example of the lat-
ter was reported by Entelos80 in their publication about 
the optimization of a phase I clinical trial protocol for a 
first- in- class therapy against type 2 diabetes mellitus 
(T2DM): their QSP simulations led to the reduction from a 
“6 arms for 14 weeks” to a “2 arms for 8 weeks” design. 
In academia, the newly acquired knowledge could per-
haps lead to the decision of developing a new research 
program, seeking a collaboration with research teams 
of bench scientists, or publishing a high- impact, peer- 
reviewed article. In a regulatory setting, the knowledge 
derived from a QSP model can translate into an approval 
(e.g., the rhPTH example11) or a rejection of the license 
application.
The impact of a QSP modeling exercise can have a rip-
ple, multifold effect beyond the modeler’s initial stakehold-
ers. The success of modeling is especially compelling when 
impact can be translated into financial figures, reflecting any 
sort of cost or time savings in a business, in an academic 
institution, or even in the national budget. The article on the 
T2DM QSP model mentioned previously80 is an example of 
QSP workflow step
Recommendations
Relevant referencesMathematical Computational
4. Model verification • Test code for consistency: 
ǫ Eliminate detected coding errors
ǫ Ensure solutions or limit conditions reached by the model are correct (e.g., 
A + B -> C yields no C when A and B are set to zero)
• Determine the steady states of the system
• Run a sensitivity analysis to identify which parameters have the most effect on 
model responses and how significant is that effect
Anderson et al. (2007)43
Hicks et al. (2015)45
Nestorov et al. (1999)67
Nestorov et al. (1997)68
Kirouac (2018)69
Thomaseth & Cobelli 
(1999)70
• When model parameters are assumed, that is, not 
supported by independent, reliable input data or 
knowledge (see 3. Input data, knowledge and 
assumptions going into the model in this table): 
ǫ Check that those parameters are identifiable
ǫ Consider techniques to establish model 
parameter redundancy
• Consider running a bifurcation analysis to define 
the scope of extrapolations from the model
• Consider model reduction methods
Walter et al. (1987)48
Janzen et al. (2016)53
Raue et al. (2014)55
Karlsson et al. (2012)56
Villaverde et al. (2019)57
Meshkat et al. (2014)58
Saccomani et al. (2010)59
Choquet et al. (2012)60
Cole et al. (2010)61
Back et al. (1992)65
Snowden et al. (2017)66
5. Model validation • Describe and clearly reference the data or knowledge used to validate the model 
and explain its relevance to the model context
• Plot model simulations overlaying the corresponding experimental data onto them 
with measures of potential/perceived variability (e.g., standard error bars, 
confidence intervals, shadows from ensemble simulations)
Anderson et al. (2007)43
Hicks et al. (2015)45
Lu et al. (2014)72
Kanodia et al. (2014)73
Ortega et al. (2013)74
Karelina et al. (2012)75
Peterson and Riggs 
(2012)76
Agoram (2014)78
6. Model results, application, and 
impact
• Articulate a clear answer to the questions originally posed for the model (see 1. 
Purpose and context of the model in this table)
• Provide the simulation plots and/or outcome numerical values that underpin 
those answers
• Qualify the type of knowledge acquired through the modeling exercise: a 
positive new discovery, a confirmation, and/or a realization of a misconception.
• Describe the decisions that the modeling exercise enabled for the different 
stakeholders (user, domain expert, academic, industry, regulatory)—qualita-
tively and, whenever possible, quantitatively
• Describe the impact of the QSP modeling exercise beyond the initial stakehold-
ers, especially if the impact is societal and/or can be translated into financial 
figures
Marshall et al. (2016)41
Shepard (2011)79
Peterson & Riggs (2015)11
Hendricks (2013)77
Kansal & Trimmer (2005)80
Milligan et al. (2013)81
Allerheiligen (2014)82
Bueters et al. (2013)83
Nayak et al. (2018)84
PharmML, pharmacometrics markup language; QSP, quantitative and systems pharmacology; SBGN, systems biology graphical notation; SBML, systems 
biology markup language.
Table 2 (Continued)
12
CPT: Pharmacometrics & Systems Pharmacology
Best Practices for QSP Models
Cucurull- Sanchez et al.
reporting this sort of impact: the authors estimated a reduc-
tion in 66% of the cost and 40% of the time length of the 
phase I trial. In the context of modeling, albeit not exclusively 
of QSP, there are a couple of significant examples by Pfizer81 
and Merck.82 Finally, there is the societal impact, including 
the enhanced 3Rs of animal usage,83 reduced patient bur-
den, or development of scientific talent among others.
Several groups have collated the impact of modeling 
and simulation, although only a limited subset of these 
would be considered QSP. The impact examples col-
lected by the American Society for Clinical Pharmacology 
and Therapeutics (ASCPT) Quantitative Pharmacology 
Network84 provide a number of case studies, including the 
key question that needed to be addressed, impact on de-
cision making, and estimated time saving. Of note are the 
translational medicine examples that generate predictions 
before clinical data are generated, including the optimiza-
tion of bispecific antibody affinities and the translation of the 
efficacy of antimicrobial agents using nonclinical data.
Reporting the impact of each QSP model developed and 
published, at all of these different levels, is of crucial impor-
tance if the QSP community aims to widen the adoption of 
this discipline.
CONCLUSIONS AND FUTURE WORK
This article attempts to summarize the considerations 
made by members of the UK QSP Network on good prac-
tice for the conduct and reporting of each stage of QSP 
model development and application. QSP is a very useful 
body of technologies but also a highly technical area, so 
the communication of both methods and results is of the 
utmost importance. In particular, sufficient information re-
garding the following should be given to enable the work to 
be reproduced:
1. The questions and objectives that the modeling ex-
ercise set out to answer and achieve
2. The modeling assumptions (biological and math e matical)
3. The sources of data and prior parameter values
4. The mathematical model structure
5. Final parameter values
6. The existence of steady states and/or oscillations
7. The computational algorithms used
8. The conclusions that the modeling supported
A summary list of all recommendations, along with refer-
ences, can be found in Table 2.
The widespread adoption of these good practices should 
facilitate not only broad adoption of QSP but also the reuse 
of existing QSP models in new and exciting areas of pharma-
cology and drug discovery. These include, just as examples, 
the possibility to build on existing QSP models to extrapolate 
the results of drug treatment between diseases with common 
underlying mechanisms (e.g., different cancer types), and 
the definition and evaluation of optimal drug combinations85 
considering the sequence and timing of a given therapy.
An area where QSP holds much promise is in pediat-
ric and vulnerable populations.86 In particular, the under-
standing of neonatal, obstetric, and fetal pharmacology is 
important. Much progress has been made in terms of ex-
trapolation from adult or adolescent data to pediatric pop-
ulations (which currently is done outside of QSP, usually via 
pharmacometric and PBPK approaches).87 However, more 
needs to be achieved in terms of understanding the on-
togeny and maturation processes (fetal development, the 
placenta exchange process, neonates, pediatrics88,89). This 
would also support hypotheses on similarities of disease 
mechanisms between different stages of development. 
Another area where multiscale models have potential is in 
their use in concert with pharmacometric models to study 
how an observed variability in patient response can be ex-
plained by, for example, variables influencing trial design, 
variation in disease- specific covariates (not exclusively 
pharmacokinetics), or the complex pathway modulation 
that can be engendered by drug combinations. This sum-
mary will hopefully serve as a helpful guidance to QSP 
practitioners seeking to maximize their impact as well as 
to other stakeholders considering the use of QSP models 
in their projects.
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